Decheng, a China Investor, Participates in Invitae's $120 Million Funding

Invitae Corporation, a  San Francisco  genetic testing company, raised a huge $120 million in a Series F funding round. One of the participants was Decheng Capital, a Shanghai-based investment company focused on life science. Invitae has developed a single test for 218 genes that are associated with significant health problems. The test, which costs only $1500, provides a genetic reading in three weeks. Invitae says the new capital be used to build its infrastructure. More details.... Share this with colleagues: // //